• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aon Declares Quarterly Dividend

    1/11/21 4:30:00 PM ET
    $AON
    $A
    Specialty Insurers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AON alert in real time by email

    DUBLIN, Jan. 11, 2021 /PRNewswire/ -- Aon plc (NYSE: AON), the leading global professional services firm providing a broad range of risk, retirement and health solutions, announced today that the Board of Directors has declared a quarterly cash dividend of $0.46 per share on outstanding Class A Ordinary Shares. The dividend is payable February 12, 2021 to shareholders of record on February 1, 2021.

    About Aon
    Aon plc (NYSE: AON) Aon is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.

    Follow Aon on Twitter: https://twitter.com/Aon_plc
    Sign up for News Alerts: http://aon.mediaroom.com/index.php?s=58

    Investor Contact:
    Investor Relations
    [email protected]
    +1 312-381-3310

    Media Contact:
    Jason Gertzen
    [email protected]
    +1 312-381-3024

    SOURCE Aon plc

    Get the next $AON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AON
    $A

    CompanyDatePrice TargetRatingAnalyst
    Aon plc
    $AON
    2/27/2026$397.00Neutral → Outperform
    Mizuho
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Aon plc
    $AON
    12/16/2025$389.00Neutral
    Mizuho
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Agilent Technologies Inc.
    $A
    12/9/2025$170.00Buy
    Goldman
    Agilent Technologies Inc.
    $A
    12/2/2025$270.00Overweight
    Morgan Stanley
    Aon plc
    $AON
    11/3/2025$402.00Neutral → Buy
    Citigroup
    More analyst ratings

    $AON
    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aon upgraded by Mizuho with a new price target

    Mizuho upgraded Aon from Neutral to Outperform and set a new price target of $397.00

    2/27/26 8:20:07 AM ET
    $AON
    Specialty Insurers
    Finance

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AON
    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Knight Lester B bought $1,276,956 worth of Class A Ordinary Stock (4,000 units at $319.24) (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    2/12/26 4:34:45 PM ET
    $AON
    Specialty Insurers
    Finance

    Director Spruell Byron bought $246,558 worth of Class A Ordinary Stock (725 units at $340.08), increasing direct ownership by 16% to 5,303 units (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    8/29/24 4:04:05 PM ET
    $AON
    Specialty Insurers
    Finance

    Knight Lester B bought $2,766,116 worth of Class A Ordinary Stock (10,000 units at $276.61) (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    5/7/24 4:39:08 PM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

    Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice Agilent Technologies Inc. (NYSE:A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories. At USCAP 2026, Agilent will feature its continued expansion in oncology

    3/19/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

    Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics' CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides cus

    3/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Myriad Venture Partners Expands Executive Advisory Board as Enterprise AI Moves Into Production

    Executive Advisory Board now includes more than 30 senior leaders from Fortune 500 and global enterprisesNEW YORK, March 11, 2026 /PRNewswire/ -- Myriad Venture Partners ("Myriad"), an early-stage venture capital firm focused on defining the future of business solutions in enterprise AI, enterprise B2B software, and industrial transformation, today announced the expansion of its Executive Advisory Board, bringing the Board to more than 30 C-suite leaders from Fortune 500 and global enterprises. New executives joining the Board include leaders from GSK, Mastercard, Harley-Davidson, Meta, Oracle, and other global companies, further strengthening Myriad's hands-on model and deepening its ties t

    3/11/26 6:00:00 AM ET
    $AON
    $GSK
    $HOG
    Specialty Insurers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AON
    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Corona Anne converted options into 367 units of Class A Ordinary Stock and covered exercise/tax liability with 163 units of Class A Ordinary Stock, increasing direct ownership by 5% to 4,195 units (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    3/17/26 4:14:48 PM ET
    $AON
    Specialty Insurers
    Finance

    CEO, Regions & North America Goltermann Lori converted options into 518 units of Class A Ordinary Stock and covered exercise/tax liability with 225 units of Class A Ordinary Stock, increasing direct ownership by 5% to 6,795 units (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    3/17/26 4:11:54 PM ET
    $AON
    Specialty Insurers
    Finance

    Global CEO, Solution Lines Marcell Andy converted options into 1,630 units of Class A Ordinary Stock and covered exercise/tax liability with 794 units of Class A Ordinary Stock, increasing direct ownership by 10% to 8,820 units (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    3/17/26 4:08:33 PM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $A
    SEC Filings

    View All

    Agilent Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/20/26 4:05:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/6/26 4:05:24 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/3/26 4:17:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AON
    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Aon Appoints Anne Corona as CEO of North America, Elevates Lori Goltermann as Vice Chair and Appoints Farheen Dam as CEO of Enterprise Clients and Chief Client Officer

    DUBLIN, March 10, 2026 /CNW/ -- Aon plc (NYSE:AON), a leading global professional services firm, announced today that it is transitioning the North America CEO role from Lori Goltermann to Anne Corona, effective immediately, and has elevated Goltermann to serve as Vice Chair of Aon, effective March 31, 2026. With this transition, Farheen Dam has been appointed to serve as CEO of Enterprise Clients and Chief Client Officer, effective immediately. Corona, Goltermann and Dam report to Aon President and CEO Greg Case and serve on the Aon Executive Committee.As CEO of North America, Corona will build on the firm's momentum in the region delivering actionable insights, differentiated Risk Capital

    3/10/26 8:30:00 AM ET
    $AON
    Specialty Insurers
    Finance

    Aon Joins Ferrari Hypersail as Premium Partner

    Aon Expands Ferrari Partnership into High-Performance Sailing, Promoting Innovation and ResilienceMILAN, Feb. 17, 2026 /CNW/ -- Aon plc (NYSE:AON), a leading global professional services firm, today announced that it will serve as the Premium Partner of Ferrari Hypersail, an unprecedented marine initiative dedicated to high-performance sailing.In 2025, Aon became an Official Partner of the Scuderia Ferrari HP Formula One team through a multi-year agreement. By extending their relationship from the racetrack to the water, Aon aims to demonstrate how resilience and better decision-making can unlock new possibilities for clients and set new standards in competitive sport. This partnership will

    2/17/26 9:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    Aon Appoints Joe Peiser as CEO of Risk Capital

    DUBLIN, Feb. 12, 2026 /PRNewswire/ -- Aon plc (NYSE:AON), a leading global professional services firm, today announced the appointment of Joe Peiser as CEO of Risk Capital.  In this role, Peiser will lead Aon's Risk Capital capabilities across Commercial Risk and Reinsurance Solutions. Peiser will continue to report to Andy Marcell, CEO of Global Solutions for Aon. A search for the role of CEO of Commercial Risk is underway. Peiser's appointment reflects Aon's broader strategy to strengthen how the firm helps clients navigate increasing volatility by connecting risk with the most efficient forms of capital. Peiser's enhanced leadership role will accelerate Aon's work to deliver solutions tha

    2/12/26 8:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AON
    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aon plc

    SC 13G - Aon plc (0000315293) (Subject)

    11/13/24 3:01:03 PM ET
    $AON
    Specialty Insurers
    Finance

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials